



Sermorelin vs. Hexarelin: Optimal Uses and Timing Based on Medical Evidence

Authors: Monis, A. and Maple, K.

Date: October 2024

Abstract

Growth hormone therapy has garnered significant interest as a potential solution for age-related declines in growth hormone levels, with sermorelin and hexarelin standing out as promising peptide options in this field. Both peptides offer unique benefits for stimulating growth hormone release, thereby contributing to overall health and vitality.

This white paper delves into the clinical research and comparative insights surrounding sermorelin and hexarelin to provide a comprehensive understanding of their specific roles, applications, and efficacy. In particular, it examines their therapeutic benefits, mechanisms of action, safety profiles, and potential applications in areas like cardiovascular health and age-related conditions.

By analyzing current evidence, this white paper offers valuable insights into the optimal use of sermorelin and hexarelin, highlighting the need for further research to evaluate their long-term effects and expand practical applications within hormone replacement therapy.

Table of Contents

Introduction	3
Problem Statement	3
Literature Review	4
Methodology	4
Results/Findings	4
Discussion	8
Conclusion	8
References	8
Appendices	11
Acknowledgments	12
Conflicts of Interest	13
Contact Information	13

Introduction

Sermorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that stimulates the release of human growth hormone (hGH) by directly acting on the pituitary gland. This peptide comprises the first 29 amino acids of GHRH, the active portion of the native hormone responsible for triggering hGH production. Discovered in the 1970s, sermorelin emerged from efforts to understand and modulate the hGH axis for therapeutic benefit, specifically targeting conditions associated with growth hormone deficiencies. Unlike direct hGH injections, sermorelin promotes a more physiological approach to growth hormone therapy by stimulating natural hGH release via the body's GHRH pathway.

Clinically, sermorelin is widely used to diagnose and treat growth deficiencies in children, but it also finds off-label application in addressing adult hGH deficiencies, supporting overall health and well-being.

Hexarelin, a synthetic growth hormone-releasing peptide (GHRP), is composed of six amino acids and operates as a growth hormone secretagogue. Acting on both pituitary and hypothalamic receptors, hexarelin effectively stimulates hGH release. Growth hormone-releasing peptides like hexarelin were first synthesized in Cyril Bowers' laboratory in 1977 as enkephalin opiate analogs capable of inducing hGH release in vitro from rat pituitary cells. Like sermorelin, hexarelin addresses growth hormone deficiencies, offering potential improvements in health and quality of life by enhancing endogenous hGH production.

Together, sermorelin and hexarelin represent significant advancements in growth hormone therapy, leveraging distinct yet complementary mechanisms to enhance natural hGH release, thereby offering more targeted and potentially safer alternatives to traditional hGH injections.

Problem Statement

The critical role of growth hormone in regulating numerous physiological functions is well-established, with research showing that hGH levels naturally decrease with age. This reduction impacts muscle mass, metabolic rate, and overall vitality. Because imbalances in growth hormone can lead to various health issues, peptides like sermorelin and hexarelin have emerged as promising solutions for stimulating natural hGH release. Although both peptides show significant potential, understanding their optimal applications in clinical settings is an area of ongoing study, highlighting the need for further research and informed discussion to maximize their therapeutic benefits.

Literature Review

This white paper draws on studies by **R.F. Walker**, **A. Prakash**, and **K.L. Goa** to examine the effects of sermorelin as a growth hormone therapy for individuals with growth hormone deficiency. Additionally, insights from **Y. Chang** and **D.K. Sinha**, along with clinical studies by **E. Arvat** and **M.V. Vitello**, reveal the promising roles of sermorelin and hexarelin in hormone therapy, metabolic health, and as potential adjunct therapies for cardiovascular and cognitive support.

Research findings provide a compelling case for the use of sermorelin and hexarelin in health management, showing that these peptides can offer far-reaching benefits. In addition to their roles in growth hormone therapy, studies by **M. Giusti**, **C. Guan**, and **R. Mosa** highlight hexarelin's significant impact on cardiovascular health, renal protection, and metabolic function. Research by **N. Filigheddu**, **X.B. Xu**, and **S. Frascarelli** further supports hexarelin's potential with findings on its anti-apoptotic effects and cardioprotective properties.

While much of the existing research on these peptides is promising, many studies remain preliminary or were conducted on animal models. To fully harness sermorelin and hexarelin's potential, updated, large-scale clinical trials are essential. These studies would provide a stronger foundation to validate and expand the use of sermorelin and hexarelin in therapeutic settings, confirming their safety, efficacy, and long-term outcomes.

For individuals and practitioners exploring advanced options in growth hormone therapy, sermorelin and hexarelin present valuable tools to support metabolic health, cardiovascular resilience, and overall vitality. Investing in these peptides could be a transformative step toward enhanced health and well-being.

Methodology

The main goal of this white paper is to review and investigate existing evidence on the physiological and therapeutic effects of sermorelin and hexarelin on endocrine, metabolic, and immune functions. The studies and articles referenced in this white paper focus on the role of sermorelin in growth hormone replacement therapy for age-related deficiencies and its influence on immune system responses and tumor suppression. The white paper also inspects the potential of hexarelin to exhibit cardioprotective, metabolic, and hormone-regulating properties.

Additionally, this white paper analyzes specific outcomes of sermorelin and hexarelin therapies across various contexts, including an aging population, people with preexisting cardiovascular or cognitive impairments, and patients with metabolic syndrome. Furthermore, the white paper addresses the potential benefits, limitations, and risks linked to these therapies, emphasizing the

need for further investigation to highlight their clinical use.

Results/Findings

In his editorial, **R.F. Walker** highlights sermorelin as a potentially superior alternative to recombinant human growth hormone (rhGH) for age-related growth hormone replacement therapy (GHRT). Unlike rhGH, sermorelin stimulates endogenous hGH production through the pituitary, offering a more controlled, physiological approach. Its mechanism reduces the risk of overdose due to natural feedback mechanisms involving somatostatin, a neuroinhibitory hormone, and allows episodic rather than continuous hormone release. Additionally, sermorelin stimulates pituitary gene transcription of hGH messenger RNA, preserving the growth hormone neuroendocrine axis—a key area that declines with age. Notably, off-label use of sermorelin is permitted under federal law, giving healthcare providers flexibility in its prescription for GHRT in adults.

A. Prakash and K.L. Goa explored sermorelin as both a diagnostic and therapeutic agent. Their study found that intravenous sermorelin rapidly induces hGH release, making it a reliable diagnostic tool for growth hormone deficiency (GHD). In children with idiopathic GHD, daily administration of sermorelin significantly increased height velocity over 12 to 36 months, although results were more modest compared to somatotropin. The study concludes that sermorelin is well-tolerated and beneficial in stimulating growth in children, though its efficacy is still less than that of direct hGH treatments.

Y. Chang et al. investigated sermorelin's potential for glioma treatment using transcriptomic data from 1,108 glioma patients. They found that sermorelin, particularly effective in patients with recurrent, high-grade gliomas, could inhibit tumor proliferation by blocking the cell cycle and enhancing immune responses. This study suggests that sermorelin penetrates the blood-brain barrier with minimal side effects, underscoring its potential as a treatment for aggressive brain tumors.

A review by **D.K. Sinha et al.** examined the effects of growth hormone secretagogues (GHS) like sermorelin in hypogonadal males and those with metabolic syndrome. Their findings show that sermorelin can improve body composition concerns linked to hypogonadism and metabolic syndrome, either alone or combined with testosterone therapy. Referencing O. Khorram's trial, Sinha also noted sermorelin's benefits in older adults, including increased lean body mass, enhanced skin thickness, and improved insulin sensitivity, overall well-being, and libido, particularly in men.

M.V. Vitello et al. found that sermorelin therapy over six months improved cognitive functions, including planning, memory, and processing speed, in healthy older adults. This research suggests sermorelin may mitigate cognitive decline, making it potentially valuable for both healthy aging and neurodegenerative conditions.

A.F. Massoud et al. explored hexarelin's effects, discovering that hexarelin, when combined with sermorelin, demonstrates synergistic effects in stimulating hGH, even in the presence of somatostatin—a hormone that normally inhibits GH release. Another study by Massoud confirmed that intravenous hexarelin induces dose-dependent release of GH, prolactin, and cortisol, with low doses amplifying the effect of GHRH.

In a clinical trial, **E. Arvat et al.** noted that hexarelin, like other GHRPs, stimulates the release of adrenocorticotropin (ACTH) and cortisol. Their study found hexarelin's effect on cortisol was comparable to human corticotropin-releasing hormone (hCRH) and demonstrated ACTH-releasing activity independent of CRH, suggesting unique applications for hexarelin in adrenal support.

Y. Mao et al. conducted a review on hexarelin's cardiovascular effects, noting its rapid improvement of left ventricular ejection fraction (LVEF) without significant changes in blood pressure or heart rate. Mao's team also referenced research by N. Filigheddu, which demonstrated hexarelin's cardioprotective effects in preventing doxorubicin-induced cell death in heart cells, further supporting hexarelin's value in protecting heart health.

M. Giusti et al. reported that hexarelin could consistently stimulate prolactin release in healthy women, though not in those with anorexia nervosa, suggesting that estrogen levels may influence hexarelin's activity. **C. Guan et al.** found hexarelin protective in renal ischemia/reperfusion injuries, reducing kidney damage and improving renal function.

Lastly, **R. Mosa et al.** demonstrated hexarelin's beneficial effects on glucose tolerance and lipid metabolism in mice, finding that hexarelin reduced fat mass, increased lean mass, and improved metabolic markers. These findings indicate that hexarelin could serve as a treatment for lipid disorders associated with metabolic syndrome.

The cumulative findings from these studies emphasize the therapeutic value of sermorelin and hexarelin across a range of health conditions, including growth hormone deficiency, metabolic syndrome, cardiovascular health, and cognitive support. While sermorelin offers a controlled, physiological alternative for growth hormone replacement, hexarelin shows promise for broader applications, from cardioprotection to improved metabolic health. Updated clinical trials, especially in human subjects, would solidify their roles in these therapeutic areas and validate their long-term safety and efficacy.

Discussion

The analysis of studies, clinical trials, and reviews on sermorelin and hexarelin has shed light on the unique benefits these peptides offer for enhancing physiological functions. **Sermorelin** stands out for its ability to stimulate endogenous human growth hormone (hGH) release, making it a valuable option for improving muscle mass, recovery, and metabolic health. Research highlights sermorelin's influence on lean body mass, particularly in male subjects, as demonstrated by **D.K. Sinha et al.** Additionally, **M.V. Vitello et al.** found that sermorelin can enhance cognitive function—a benefit that could indirectly support physical performance through improved focus and coordination during exercise.

On the other hand, **hexarelin** has shown robust growth hormone-releasing effects, with **A.F. Massoud et al.** reporting its powerful activity and synergy when combined with GHRH analogs. This combination can maximize growth hormone response, offering potential advantages for those seeking to enhance muscle strength. Moreover, hexarelin's cardioprotective effects, documented by **Y. Mao et al.**, suggest it may support heart health, making it a versatile peptide with applications beyond growth hormone stimulation.

Despite the promising findings, the current body of evidence for both peptides is limited by its reliance on older studies, with few comprehensive, long-term safety profiles available. This underscores the need for updated research to verify and expand on these peptides' therapeutic potential.

Selecting the appropriate peptide depends on individual goals. **Sermorelin** is an excellent option for individuals, particularly older adults, looking to boost hGH levels through natural pathways, thereby minimizing risks associated with exogenous hormone administration. **Hexarelin** may be better suited for those requiring potent growth hormone stimulation within a clinical setting. Further research would refine the roles of sermorelin and hexarelin, optimizing their use for maximum therapeutic benefit and providing clearer guidelines for their safe, effective application.

Conclusion

The findings in this white paper strongly suggest that both sermorelin and hexarelin hold substantial promise for individuals seeking to enhance muscle strength, improve body composition, and support overall health. **Sermorelin** works by stimulating the body's natural production of growth hormone, leading to improved lean body mass, better metabolic regulation, and a more natural approach to boosting growth hormone levels. For those who want the benefits of growth hormone without the risks of direct hormone injections, sermorelin offers a safer and more physiological alternative.

Hexarelin, known for its potent growth hormone-releasing properties, stands out as a powerful tool for those aiming to maximize their body's growth hormone response. Hexarelin's effects extend beyond muscle enhancement; it has demonstrated cardioprotective benefits, supporting heart health and resilience, and has shown potential in aiding recovery from acute kidney injuries. This peptide is ideal for those who need a stronger growth hormone stimulus within a controlled environment, providing both strength gains and broader health benefits.

Although most studies on sermorelin and hexarelin are based on earlier research, the consistency of their results points to their considerable value. Investing in these peptides now allows you to tap into their extensive health and fitness benefits while awaiting the expanded body of research. With sermorelin and hexarelin, you gain access to a dual approach to growth hormone support that promotes not only physical performance but also overall wellness—making them compelling options for anyone seeking a well-rounded, science-backed boost in health.

References

Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. *Sex Med Rev.* 2018;6(1):45-53. doi:10.1016/j.sxmr.2017.02.004

Hage C, Salvatori R. Growth Hormone and Aging. *Endocrinol Metab Clin North Am.* 2023;52(2):245-257. doi:10.1016/j.ecl.2022.10.003

Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?. *Clin Interv Aging.* 2006;1(4):307-308. doi:10.2147/ciia.2006.1.4.307

Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. *BioDrugs*. 1999;12(2):139-157. doi:10.2165/00063030-199912020-00007

Chang Y, Huang R, Zhai Y, et al. A potentially effective drug for patients with recurrent glioma: sermorelin. *Ann Transl Med*. 2021;9(5):406. doi:10.21037/atm-20-6561

Sinha DK, Balasubramanian A, Tatem AJ, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. *Transl Androl Urol*. 2020;9(Suppl 2):S149-S159. doi:10.21037/tau.2019.11.30

Gelander L, Lindstedt G, Selstam G, Wide L, Albertsson-Wikland K. Effects of acute intravenous injection of two growth hormone-releasing hormones (GHRH 1-40 and 1-29) on serum growth hormone and other pituitary hormones in short children with pulsatile growth hormone secretion. *Horm Res*. 1989;31(5-6):213-220. doi:10.1159/000181119

Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH₂ in age-advanced men and women. *J Clin Endocrinol Metab*. 1997;82(5):1472-1479. doi:10.1210/jcem.82.5.3943

Vitiello MV, Moe KE, Merriam GR, Mazzone G, Buchner DH, Schwartz RS. Growth hormone releasing hormone improves the cognition of healthy older adults. *Neurobiol Aging*. 2006;27(2):318-323. doi:10.1016/j.neurobiolaging.2005.01.010

Massoud AF, Hindmarsh PC, Brook CG. Interaction of the growth hormone releasing peptide hexarelin with somatostatin. *Clin Endocrinol (Oxf)*. 1997;47(5):537-547. doi:10.1046/j.1365-2265.1997.3121128.x

Massoud AF, Hindmarsh PC, Brook CG. Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study. *J Clin Endocrinol Metab*. 1996;81(12):4338-4341. doi:10.1210/jcem.81.12.8954038

Massoud AF, Hindmarsh PC, Brook CG. Hexarelin induced growth hormone release is influenced by exogenous growth hormone. *Clin Endocrinol (Oxf)*. 1995;43(5):617-621. doi:10.1111/j.1365-2265.1995.tb02927.x

Arvat E, Maccagno B, Ramunni J, et al. Hexarelin, a synthetic growth-hormone releasing peptide, shows no interaction with corticotropin-releasing hormone and vasopressin on adrenocorticotropin and cortisol secretion in humans. *Neuroendocrinology*. 1997;66(6):432-438. doi:10.1159/000127269

Mao Y, Tokudome T, Kishimoto I. The cardiovascular action of hexarelin. *J Geriatr Cardiol*. 2014;11(3):253-258. doi:10.11909/j.issn.1671-5411.2014.03.007

Filigheddu N, Fubini A, Baldanzi G, et al. Hexarelin protects H9c2 cardiomyocytes from doxorubicin-induced cell death. *Endocrine*. 2001;14(1):113-119. doi:10.1385/ENDO:14:1:113

Xu XB, Pang JJ, Cao JM, et al. GH-releasing peptides improve cardiac dysfunction and cachexia and suppress stress-related hormones and cardiomyocyte apoptosis in rats with heart failure. *Am J Physiol Heart Circ Physiol*. 2005;289(4):H1643-H1651. doi:10.1152/ajpheart.01042.2004


Frascarelli S, Ghelardoni S, Ronca-Testoni S, Zucchi R. Effect of ghrelin and synthetic growth hormone secretagogues in normal and ischemic rat heart. *Basic Res Cardiol*. 2003;98(6):401-405. doi:10.1007/s00395-003-0434-7

Giusti M, Foppiani L, Ponzani P, Cuttica CM, Falivene MR, Valenti S. Hexarelin is a stronger GH-releasing peptide than GHRH in normal cycling women but not in anorexia nervosa. *J Endocrinol Invest*. 1997;20(5):257-263. doi:10.1007/BF03350297

Guan C, Li C, Shen X, et al. Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway. *Eur J Med Res*. 2023;28(1):344. Published 2023 Sep 14. doi:10.1186/s40001-023-01318-w


Mosa R, Huang L, Wu Y, et al. Hexarelin, a Growth Hormone Secretagogue, Improves Lipid Metabolic Aberrations in Nonobese Insulin-Resistant Male MKR Mice. *Endocrinology*. 2017;158(10):3174-3187. doi:10.1210/en.2017-00168

Appendices



Sermorelin is the most effective drug for recurrent glioma patients.

Chang Y, Huang R, Zhai Y, et al. A potentially effective drug for patients with recurrent glioma: sermorelin. *Ann Transl Med.* 2021;9(5):406. doi:10.21037/atm-20-6561



Hexarelin relieved apoptosis following ischemic/reperfusion-induced acute kidney injury.

Guan C, Li C, Shen X, et al. Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway. *Eur J Med Res.* 2023;28(1):344. Published 2023 Sep 14.
doi:10.1186/s40001-023-01318-w

Acknowledgments

The authors of this white paper acknowledge Walker R.F, Prakash A, Goa K.L, Chang Y, Sinha D.K, Gelander L, Khorram O, Vitello M.V, Massoud A.F, Arvat E, Mao Y, N. Filigheddu, Xu X.B,

Frascarelli S, Giusti M, Guan C, and Mosa R. for their invaluable contributions to previous research, clinical trials, and reviews. It is their hard work and dedication that helped shape our understanding of the effectiveness and different applications of sermorelin and hexarelin thereby making it possible for us to reach meaningful conclusions in this white paper.

Conflicts of Interest

Dr. Vitello held the function of a scientific consultant for Serono Laboratories Inc. and Dr. Schwarz also served as a scientific consultant and received research support and held lectures supported by Serono Laboratories Inc.

Contact Information

For any questions or inquiries regarding this white paper, please feel free to contact the authors directly.